Literature DB >> 34048219

Antipoxvirus Activity Evaluation of Optimized Corroles Based on Development of Autofluorescent ANCHOR Myxoma Virus.

Sandrine Kappler-Gratias1, Léo Bucher2, Sokunthea Top1,3, Charlotte Quentin-Froignant1,3, Nicolas Desbois2, Stéphane Bertagnoli3, Matthieu Louison3, Emma Monge3, Alain Bousquet-Melou4, Marlène Lacroix4, Claude P Gros2, Franck Gallardo1.   

Abstract

A series of 43 antiviral corrole-based molecules have been tested on myxoma virus (Lausanne-like T1MYXV strain). An autofluorescent MYXV, with an ANCHOR cassette, has been used for the studies. A2B-fluorocorroles display various toxicities, from 40 being very toxic (CC50 = 1.7 μM) to nontoxic 38 (CC50 > 50 μM), whereas A3-fluorocorroles, with one to three fluorine atoms, are not toxic (with the exception of corroles 9, 10, and 22). In vitro, these compounds show a good selectivity index when used alone. Corrole 35 seems to be the most promising compound, which displays a high selectivity index with the lowest IC50. Interestingly, this "Hit" corrole is easy to synthesize in a two-step reaction. Upscaling production up to 25 g has been carried out for in vivo tests. In vivo studies on New Zealand white rabbits infected with myxoma virus show that symptoms are delayed and animal weight is increased upon treatment, while no acute toxicity of the corrole molecule was detected.

Entities:  

Keywords:  antiviral; corrole; dsDNA virus; myxoma virus; poxvirus; resistant strain

Year:  2021        PMID: 34048219     DOI: 10.1021/acsinfecdis.1c00068

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  1 in total

1.  Evaluation of Commercial Myxomatosis Vaccines against Recombinant Myxoma Virus (ha-MYXV) in Iberian Hare and Wild Rabbit.

Authors:  Fábio A Abade Dos Santos; Carina L Carvalho; Pâmela C L G Valente; Henrique Armés; Sylvia S Reemers; Maria C Peleteiro; Inés Calonge Sanz; Kevin P Dalton; Francisco Parra; Margarida D Duarte
Journal:  Vaccines (Basel)       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.